Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemo-therapy significantly improved overall survival, leading to FDA approval.
Cell 168, February 9, 2017 Published by Elsevier Inc.
Click here to original publication.